Quarterly report pursuant to Section 13 or 15(d)

Supplemental Information

v3.24.3
Supplemental Information
9 Months Ended
Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Supplemental Information

3. Supplemental Information

Concentrations of Credit Risk

Our financial instruments that are exposed to concentrations of credit risk consist primarily of cash and trade accounts receivable. Although we limit our exposure to credit loss by depositing our cash with established financial institutions that management believes have good credit ratings and represent minimal risk of loss of principal, our deposits, at times, may exceed federally insured limits. Collateral is not required for accounts receivable, and we believe the carrying value approximates fair value. The following table sets forth our concentration of accounts receivable, net of specific allowances for credit losses.

 

 

 

September 30, 2024

 

December 31, 2023

Customer A

 

-%

 

43%

Customer B

 

10%

 

16%

Customer C

 

2%

 

12%

Customer D

 

21%

 

-%

Customer E

 

14%

 

-%

Customer F

 

11%

 

-%

 

Discontinued Operation

On November 1, 2023, the Company made the strategic decision to wind down and discontinue the operations of its Lyte reporting segment. We generally completed the wind down of the Lyte operations as of December 31, 2023.

A summary of the Lyte discontinued operation in the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2023 is set forth below:

 

 

 

Three months ended

 

 

Nine months ended

 

 

 

September 30, 2023

 

Net revenues

 

$

1,539

 

 

$

7,133

 

Cost of revenues

 

 

1,975

 

 

 

7,361

 

Gross profit

 

 

(436

)

 

 

(228

)

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

Sales and marketing

 

 

188

 

 

 

791

 

General and administrative

 

 

493

 

 

 

1,562

 

Impairment of goodwill

 

 

4,145

 

 

 

5,348

 

Total operating expenses

 

 

4,826

 

 

 

7,701

 

Operating loss

 

$

(5,262

)

 

$

(7,929

)

 

Goodwill Impairment

 

Goodwill arises from purchase business combinations and is measured as the excess of the cost of the business acquired over the sum of the acquisition-date fair values of tangible and identifiable intangible assets acquired, less any liabilities assumed. In

accordance with ASC 350, Intangibles — Goodwill and Other, we do not amortize goodwill but rather assess its carrying value for indications of impairment annually, or more frequently if events or changes in circumstances indicate that the carrying amount may be impaired.

We performed a quantitative assessment as of September 30, 2023, using a discounted cash flow model. Based on the analysis performed, we concluded that the carrying amount of our reporting unit exceeded its respective fair value resulting in non-cash impairment charge of $9,043 for the three months ended September 30, 2023.

The goodwill impairment analysis referenced above used the discounted cash flow model (income approach) utilizing Level 3 unobservable inputs. Significant assumptions in this analysis included, but were not limited to, future cash flow projections, the weighted average cost of capital, the terminal growth rate and the tax rate. Estimates of future cash flows are based on current regulatory and economic climates, recent operating results, and planned business strategies. These estimates could be negatively affected by changes in federal, state, or local regulations or economic downturns. Future cash flow estimates are, by their nature, subjective and actual results may differ materially from estimates. We believe the assumptions and estimates utilized are both reasonable and appropriate.

 

Loss per Common Share

 

Basic loss per common share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted loss per common share is computed by giving effect to all potential shares of common stock, including those related to our outstanding warrants and stock equity plans, to the extent dilutive. For all periods presented, these shares were excluded from the calculation of diluted loss per share of common stock because their inclusion would have been anti-dilutive. As a result, diluted loss per common share is the same as basic loss per common share for all periods presented.

The following table sets forth common stock equivalents that have been excluded from the computation of dilutive weighted average shares outstanding as their inclusion would have been anti-dilutive:

 

 

 

September 30,

 

 

 

2024

 

 

2023

 

Warrants

 

 

-

 

 

 

68,877

 

Options

 

 

3,705

 

 

 

17,610

 

Restricted stock units

 

 

50,525

 

 

 

148,925

 

Total

 

 

54,230

 

 

 

235,412